Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Previous studies examining COVID-19 vaccine efficacy in hemodialysis patients primarily focused on the Alpha and Delta variants, reporting substantial protection after two-dose mRNA vaccination. However, evidence on the effectiveness of booster vaccination during the Omicron-dominant period remains limited. This study assessed the effectiveness of a third mRNA vaccine dose during the Omicron period, comparing protection against infection, hospitalization, and mortality between vaccine types.
A retrospective nationwide cohort study included Korean HD patients aged ≥18 years vaccinated with two or three doses of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine prior to January 16, 2022. Data on vaccination status, SARS-CoV-2 infections, hospitalizations, and deaths were extracted from the Korea Disease Control and Prevention Agency–National Health Insurance Service (K-COV-N) database. Cox proportional hazards were used to calculate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs).
Among 66,389 HD patients (mean age: 65.7±12.9 years; 60.5% male), 55,125 (83%) received three vaccine doses and 11,264 (17%) received two doses. Three-dose vaccination significantly reduced the risks of SARS-CoV-2 infection (aHR 0.58; 95% CI 0.56–0.60), hospitalization (aHR 0.65; 95% CI 0.62–0.70), and 30-day mortality (aHR 0.35; 95% CI 0.30–0.41) compared with two doses. Patients vaccinated with mRNA-1273 showed significantly lower risks of infection (aHR 0.84; 95% CI 0.80–0.88) and hospitalization (aHR 0.80; 95% CI 0.72–0.88) compared to those vaccinated with BNT162b2.
A third mRNA COVID-19 vaccine dose substantially enhanced protection against SARS-CoV-2 infection and severe outcomes in HD patients during the Omicron period, with the mRNA-1273 vaccine demonstrating superior effectiveness compared to BNT162b2. Booster vaccination strategies are essential to reduce severe COVID-19 outcomes in this high-risk population.
